



**ACGIH**<sup>®</sup>

1330 Kemper Meadow Drive Cincinnati, OH 45240-4148, USA

Phone: 513-742-2020 Fax: 513-742-3355

E-Mail: [mail@acgih.org](mailto:mail@acgih.org) <http://www.acgih.org>

---

Defining the Science of Occupational and Environmental Health<sup>®</sup>

January 30, 2015

David A. Pavlich  
Association Manager  
Synthetic Amorphous Silica and Silicate Industry

Re: Calcium silicate, naturally occurring as wollastonite and Calcium silicate, synthetic nonfibrous

Dear Mr. Pavlich,

**Calcium silicate, naturally occurring as Wollastonite**

The ACGIH<sup>®</sup> Board of Directors voted to retain Calcium silicate, naturally occurring as Wollastonite on the 2015 Notice of Intended Change (NIC). The proposed recommendation is a TLV<sup>®</sup>-TWA of 1 mg/m<sup>3</sup>, Inhalable particulate matter, containing no asbestos and < 1% crystalline silica with an A4, Not Classifiable as a Human Carcinogen carcinogenicity notation. While Calcium silicate, naturally occurring as Wollastonite is on the NIC, all correspondence will be considered and discussed.

We have attached a copy of the 2015 NIC draft *Documentation* for Calcium silicate, naturally occurring as Wollastonite for your personal use and review. We welcome further input in response to a review of the NIC draft *Documentation*. Your input is valued by ACGIH<sup>®</sup>, and is being carefully considered. The draft *Documentation* is also available to the public via the ACGIH<sup>®</sup> website at [www.acgih.org/store](http://www.acgih.org/store).

**Calcium silicate, synthetic nonfibrous**

The ACGIH<sup>®</sup> Board of Directors voted to place Calcium silicate, synthetic nonfibrous on the 2015 NIC with a proposal to withdraw the currently adopted recommendation of a TLV<sup>®</sup>-TWA of 10 mg/m<sup>3</sup>, containing no asbestos and < 1% crystalline silica with an A4 carcinogenicity notation referring one to Appendix B: Particles Not Otherwise Specified of the *TLVs<sup>®</sup> and BEIs<sup>®</sup>* book.

As general practice, ACGIH<sup>®</sup> reviews all submissions of comments regarding chemical substances and physical agents on the Under Study list, as well as Notice of Intended Changes (NICs) or Notice of Intent to Establish (NIEs), or currently adopted BEI(s)<sup>®</sup> or TLV(s)<sup>®</sup>. The comment period for an NIC or NIE draft *Documentation* and its respective TLV(s)<sup>®</sup>, notations, or BEIs<sup>®</sup> is limited to a firm 4-month period, running from February 1 to May 31 of each year.

ACGIH<sup>®</sup> has structured the comment period to ensure that all comments are received in time for full consideration by the appropriate committee before its fall meeting. Because of the time to properly review, evaluate, and consider comments during the fall meetings, any comments received after the deadline of May 31 may not be considered in that year's deliberations regarding the outcome for possible adoption of a NIC or NIE. All comments received after the May 31 deadline will be fully considered in the following year. All draft *Documentation* will be available for public review and comment during the full four-month period.

When submitting comments, ACGIH® requires that the submission be limited to 10 pages in length, including an executive summary. The submission may include appendices of citable material not included as part of the 10-page limit. It would be very beneficial to structure comments as follows:

1. **Executive Summary**--Provide an Executive Summary with a limit of 250 words.
2. **List of Recommendations/Actions**--Identify, in a vertical list, specific recommendations/actions that are being requested.
3. **Rationale**--Provide specific rationale to justify each recommendation/action requested.
4. **Citable Material**--Provide citable material to substantiate the rationale. Citable material is data that is available in the public domain or that we have written authorization from the owner to use. For unpublished data/studies, it is important for this authorization to accompany the submission and it must grant ACGIH® permission to use, cite, and release the data. Please refer to our website at <http://www.acgih.org/TLV/DevProcess.htm> for instructions on how to complete this permission statement.

Please visit the ACGIH® website ([www.acgih.org](http://www.acgih.org)) for complete information regarding the TLV®/BEI® Development Process.

Regards,



Ryan Peltier  
Science and Education Manager  
ACGIH®